During the period 1948-1977, vaccine research was defined by diversification of production platforms, including embryonated eggs, duck embryo cell culture, and human diploid cell lines, guiding rubella and rabies vaccine development and generating cross-species safety data across animal and human studies. Influenza vaccine strategies emphasized aerosolized inactivated formulations, with dose- and route-dependent antigenicity analyses and the involvement of neuraminidase-directed antibodies in protective responses. Meningococcal polysaccharide vaccines emerged as core public health tools, with early group C and serogroup A formulations undergoing field trials and safety testing that shaped vaccination policy. Rubella vaccine development and related immunity outcomes provided durability data for vaccine-induced protection, including trials and reinfection studies. Global vaccine research coordination intensified through cross-border program reviews and field studies that guided testing and implementation. Historical Significance: The convergence of production platforms, immunogenicity studies, and standardized assays established a blueprint for rapid, cross-species vaccine development, setting the stage for later conjugate vaccines and global immunization strategies. Breakthroughs in vaccine potency testing (hemagglutination-inhibition assays and SRID) and in neuraminidase-related immunity expanded the protective toolkit and redefined quality control standards. The demonstrated feasibility and impact of group C polysaccharide vaccines, the rubella vaccine era, and the neuraminidase protection concept created foundational knowledge that shaped subsequent vaccine design, policy, and international coordination.